Targeting Apelinergic System in Cardiometabolic Disease.
BACKGROUND
Global burden of cardiometabolic disease warrants development of newer treatment strategies. Apelin is ubiquitously expressed endogenous peptide which is a ligand for the apelinergic (APJ) receptor. Apelin/APJ receptors regulate a variety of biological functions and have been implicated in cardiovascular and metabolic homeostasis. Consequently, the apelinergic pathway represents an attractive target to treat conditions associated with cardiometabolic syndrome.


OBJECTIVE
This review highlights the important regulatory role played by apelin in energy metabolism and cardiovascular function, and potential avenues that could be harnessed for therapeutic benefit.


CONCLUSIONS
Apelin/APJ system is a druggable target to treat or prevent a variety of cardiometabolic diseases.
Rui
R
Guo
Olivia
O
Rogers
Center for Cardiovascular Research and Alternative Medicine, University of Wyoming, School of Pharmacy, College of Health Sciences, Laramie, WY 82071, United States.
Sreejayan
S
Nair
D000818:Animals; D000073861:Apelin / Q000819:agonists / Q000378:metabolism; D000075244:Apelin Receptors / Q000819:agonists / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000378:metabolism; D004734:Energy Metabolism / Q000187:drug effects; D006801:Humans; D050356:Lipid Metabolism; D008659:Metabolic Diseases / Q000188:drug therapy* / Q000378:metabolism; D058990:Molecular Targeted Therapy; D015398:Signal Transduction / Q000187:drug effects
C115436:APLN protein, human; C104575:APLNR protein, human; D000073861:Apelin; D000075244:Apelin Receptors
Apelin; apelinergic receptor; cardiovascular disease; diabetes; energy metabolism; metabolic syndrome; polymorphism